Your browser is no longer supported. Please, upgrade your browser.
CLVS Clovis Oncology, Inc. daily Stock Chart
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-7.51 Insider Own0.60% Shs Outstand53.69M Perf Week5.08%
Market Cap532.60M Forward P/E- EPS next Y-4.98 Insider Trans-12.45% Shs Float53.07M Perf Month7.71%
Income-400.20M PEG- EPS next Q-1.71 Inst Own68.20% Short Float48.32% Perf Quarter41.51%
Sales134.10M P/S3.97 EPS this Y-80.50% Inst Trans-31.92% Short Ratio2.47 Perf Half Y68.42%
Book/sh-1.60 P/B- EPS next Y32.70% ROA-52.50% Target Price15.03 Perf Year-60.82%
Cash/sh6.60 P/C1.50 EPS next 5Y61.20% ROE- 52W Range2.93 - 32.05 Perf YTD-4.84%
Dividend- P/FCF- EPS past 5Y-19.10% ROI-50.10% 52W High-76.12% Beta3.35
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin79.00% 52W Low161.25% ATR0.90
Employees468 Current Ratio3.80 Sales Q/Q64.90% Oper. Margin- RSI (14)36.40 Volatility10.78% 8.74%
OptionableYes Debt/Eq- EPS Q/Q-0.80% Profit Margin- Rel Volume1.55 Prev Close9.92
ShortableYes LT Debt/Eq- EarningsFeb 24 AMC Payout- Avg Volume10.38M Price7.65
Recom2.70 SMA20-19.05% SMA50-23.95% SMA200-18.63% Volume12,207,482 Change-22.84%
Jan-08-20Reiterated H.C. Wainwright Buy $36 → $27
Nov-19-19Downgrade Evercore ISI Outperform → In-line $8
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Feb-25-20 10:12AM  Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat Zacks -22.84%
02:06AM  Edited Transcript of CLVS earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-24-20 06:15PM  Clovis Oncology (CLVS) Reports Q4 Loss, Tops Revenue Estimates Zacks -9.82%
04:05PM  Clovis Oncology Announces 2019 Operating Results Business Wire
Feb-21-20 11:30AM  Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year? Zacks
Feb-19-20 10:13AM  What's in Store for Aimmune (AIMT) This Earnings Season? Zacks +12.96%
09:39AM  Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4? Zacks
08:39AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Feb-17-20 12:30PM  Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
08:46AM  5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates Zacks
Feb-13-20 08:30AM  Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24 Business Wire
Feb-11-20 04:05PM  Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference Business Wire
Feb-06-20 03:34PM  4 Stocks Looking Higher During Earnings Season Benzinga
11:17AM  Four stocks to watch this week include Clovis Oncology and 3D Systems MarketWatch
Feb-03-20 09:44AM  Is a Beat in the Cards for Humana's (HUM) Earnings in Q4? Zacks
04:00AM  Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France Business Wire
Jan-31-20 08:16AM  Have Insiders Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares? Simply Wall St.
Jan-28-20 04:22PM  Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study Zacks
Jan-22-20 03:56PM  You can bring your skis to this Bay Area tech bank's new downtown Denver office American City Business Journals
09:45AM  Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks
Jan-16-20 09:09AM  Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review Zacks
Jan-15-20 04:11PM  Why This Highly Rated Biotech Stock Jumped As High As 26% Investor's Business Daily +5.96%
09:27AM  Clovis Oncology's stock soars after FDA accepts sNDA for prostate cancer treatment MarketWatch
08:00AM  Clovis Oncologys Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer Business Wire
Jan-14-20 03:12PM  Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020 Zacks
Jan-07-20 07:26AM  Clovis Oncology Announces Debt Refinancing Transaction Business Wire -8.43%
07:25AM  Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019 Business Wire
Jan-02-20 08:55AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 12:08PM  FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug Zacks
Dec-18-19 10:31AM  Corporate News for Dec 18, 2019 Zacks
Dec-16-19 08:30AM  Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium Business Wire -5.83%
Dec-10-19 08:35AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks +12.98%
Dec-09-19 07:18AM  Cramer Gives His Take On Bank Of America, BlackBerry And More Benzinga +11.45%
Dec-08-19 03:16PM  Did Hedge Funds Drop The Ball On Clovis Oncology Inc (CLVS) ? Insider Monkey
Dec-07-19 11:31AM  Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue? Zacks
Dec-06-19 01:41PM  ESG and Mission-Critical Issues for Director & Officer Liability +8.47%
Dec-04-19 10:41AM  Immunomedics Resubmits Application for Breast Cancer Drug Zacks
Dec-02-19 05:41AM  Introducing Clovis Oncology (NASDAQ:CLVS), The Stock That Tanked 76% Simply Wall St. +10.05%
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks +20.31%
11:01AM  Clovis Oncology, Inc. (CLVS) Shares March Higher, Can It Continue? Zacks
Nov-27-19 09:00AM  Clovis (CLVS) Looks Good: Stock Adds 6.3% in Session Zacks +13.64%
Nov-26-19 09:00AM  Clovis (CLVS) Upgraded to Buy: Here's Why Zacks +6.33%
Nov-22-19 12:56PM  3 Momentum Stocks To Watch Post-Earnings Benzinga +11.60%
12:50PM  Three momentum stocks to watch after company earnings reports MarketWatch
Nov-19-19 04:54PM  Teva, Bausch Could Be Next to File for Bankruptcy +10.34%
Nov-14-19 01:31PM  Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
Nov-13-19 05:51AM  Edited Transcript of CLVS earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents +19.85%
04:00AM  Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy Business Wire
Nov-11-19 10:29AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks -8.50%
Nov-08-19 10:49AM  Were Hedge Funds Right About Dumping Clovis Oncology Inc (CLVS)? Insider Monkey +36.11%
09:32AM  Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
Nov-07-19 09:25AM  Clovis Oncology (CLVS) Reports Q3 Loss, Tops Revenue Estimates Zacks +20.50%
08:00AM  Clovis Oncology Announces Third Quarter 2019 Operating Results Business Wire
07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Oct-31-19 10:34AM  Analysts Estimate Clovis Oncology (CLVS) to Report a Decline in Earnings: What to Look Out for Zacks -6.76%
Oct-22-19 08:30AM  Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7 Business Wire
Oct-11-19 09:19AM  Clovis Oncology Announces Rubraca® (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund Business Wire
Oct-09-19 11:22AM  Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook Zacks
Oct-08-19 11:08AM  Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks Benzinga -12.22%
Oct-04-19 10:31AM  J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug Zacks
Oct-02-19 07:47AM  Is Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Fair? Simply Wall St.
Sep-30-19 09:00AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Sep-29-19 02:30AM  Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019 Business Wire
Sep-25-19 11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
Sep-24-19 02:08PM  Clovis Oncology Call Volume Spikes After Downgrade Schaeffer's Investment Research -6.87%
11:36AM  Clovis Gains Rights to Pre-Clinical Cancer Program for $12M Zacks
08:58AM  Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed
08:12AM  The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger Benzinga
Sep-23-19 04:00AM  Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals Business Wire
Sep-12-19 04:00AM  Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019 Business Wire -5.31%
Sep-04-19 06:00AM  Near an All-Time Low, Is Clovis Oncology a Buy? Motley Fool
Aug-31-19 09:32AM  Why Is Clovis (CLVS) Down 36.8% Since Last Earnings Report? Zacks
Aug-28-19 08:05AM  Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference Business Wire
Aug-22-19 05:42PM  Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Companys 4.50% Convertible Senior Notes Due 2024 Business Wire
Aug-19-19 10:15AM  Clovis Oncology Inc (CLVS) President and CEO Patrick J Mahaffy Bought $279,500 of Shares +6.25%
Aug-18-19 10:18AM  Who Has Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares? Simply Wall St.
Aug-13-19 10:58AM  AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis Benzinga
Aug-08-19 11:56PM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool -35.01%
06:26PM  Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes Business Wire
Aug-07-19 04:10PM  Clovis Oncology to Offer $225 Million of Convertible Senior Notes Business Wire
Aug-06-19 07:58PM  Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.32%
Aug-02-19 10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
06:24AM  Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 01:11PM  Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today Motley Fool -15.92%
Jul-25-19 10:33AM  Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-24-19 09:00AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-18-19 08:00AM  Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1 Business Wire -6.16%
Jul-16-19 10:51AM  Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study Zacks
Jul-12-19 03:18PM  Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price? Simply Wall St.
Jul-02-19 08:37AM  Do Options Traders Know Something About Clovis (CLVS) Stock We Don't? Zacks -5.99%
Jun-24-19 08:33AM  Pfizer's Talzenna Gets Approval in Europe for Breast Cancer Zacks -11.30%
Jun-18-19 08:59AM  AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use Zacks
Jun-13-19 11:51AM  Is Clovis Oncology Inc (CLVS) A Good Stock To Buy? Insider Monkey
Jun-07-19 07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 04:05PM  Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair Business Wire
09:31AM  Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report? Zacks
Jun-01-19 07:30AM  Expanded Rubraca® (Rucaparib) Data from Clovis Oncologys ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting Business Wire
May-29-19 04:23PM  Biotech Stocks Clobbered As Two Slammed With Sell Ratings Investor's Business Daily
10:08AM  Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MUEHL DANIEL WSee RemarksFeb 04Sale8.4110,47288,07015,117Feb 06 04:19 PM
IVERS-READ GILLIAN CSee RemarksFeb 04Sale8.417,20460,586203,067Feb 06 04:16 PM
Rolfe LindseySee RemarksFeb 04Sale8.417,50363,10033,722Feb 06 04:15 PM
Gross Paul EdwardSee RemarksFeb 04Sale8.4110,47088,05311,944Feb 06 04:15 PM
Rolfe LindseySee RemarksDec 20Sale11.301,72919,53826,228Dec 26 04:16 PM
IVERS-READ GILLIAN CSee RemarksDec 20Sale11.308309,379195,274Dec 26 04:15 PM
MUEHL DANIEL WSee RemarksDec 03Sale14.594666,7999,626Dec 05 04:06 PM
Rolfe LindseySee RemarksDec 03Sale14.606749,84124,185Dec 05 04:06 PM
IVERS-READ GILLIAN CSee RemarksDec 03Sale14.595928,640193,852Dec 05 04:05 PM
Gross Paul EdwardSee RemarksDec 03Sale14.594666,7996,192Dec 05 04:05 PM
MUEHL DANIEL WSee RemarksNov 26Sale10.202422,4689,369Nov 29 04:05 PM
IVERS-READ GILLIAN CSee RemarksSep 20Sale4.808374,018193,509Sep 24 04:46 PM
Rolfe LindseySee RemarksSep 20Sale4.801,7448,37123,881Sep 24 04:45 PM
Rolfe LindseySee RemarksSep 04Sale5.217163,73021,875Sep 06 04:45 PM
MUEHL DANIEL WSee RemarksSep 04Sale5.214952,5798,772Sep 06 04:45 PM
Gross Paul EdwardSee RemarksSep 04Sale5.214952,5795,642Sep 06 04:45 PM
IVERS-READ GILLIAN CSee RemarksSep 04Sale5.216303,282192,113Sep 06 04:45 PM
MUEHL DANIEL WSee RemarksAug 27Sale6.092391,4568,528Aug 28 04:15 PM
ATWOOD BRIAN GDirectorAug 20Option Exercise0.2925,8627,50025,862Aug 22 04:15 PM
BLAIR JAMES CDirectorAug 20Buy5.9720,000119,40020,000Aug 20 09:49 PM
BLAIR JAMES CDirectorAug 16Buy5.7020,000114,00033,439Aug 20 09:49 PM
MAHAFFY PATRICK JPresident and CEOAug 16Buy5.5950,000279,576968,787Aug 19 08:35 AM
SPICKSCHEN THORLEFDirectorAug 16Buy5.678,60048,76258,176Aug 16 05:45 PM
SPICKSCHEN THORLEFDirectorAug 14Buy5.469,20050,23249,576Aug 15 04:12 PM
KLINGENSTEIN PAUL HDirectorJul 29Option Exercise0.2925,8627,50059,327Jul 31 04:24 PM
Rolfe LindseySee RemarksJun 20Sale14.701,72825,40221,591Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 20Sale14.7082912,186191,788Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 04Sale15.075778,695190,357Jun 06 04:48 PM
MUEHL DANIEL WSee RemarksJun 04Sale15.074536,8277,905Jun 06 04:46 PM
Gross Paul EdwardSee RemarksJun 04Sale15.074536,8274,001Jun 06 04:45 PM
Rolfe LindseySee RemarksJun 04Sale15.076559,87119,537Jun 06 04:45 PM
MUEHL DANIEL WSee RemarksMay 29Sale14.882714,0327,643May 31 05:01 PM
IVERS-READ GILLIAN CSee RemarksMar 20Sale26.1383021,688190,007Mar 21 05:00 PM
Rolfe LindseySee RemarksMar 20Sale26.131,72945,17919,224Mar 21 04:57 PM
BLAIR JAMES CDirectorMar 14Sale27.7917,056473,9860Mar 18 04:53 PM
Gross Paul EdwardSee RemarksMar 05Sale29.291,32538,8092,577Mar 06 04:47 PM
IVERS-READ GILLIAN CSee RemarksMar 05Sale29.291,61147,186187,507Mar 06 04:47 PM
Rolfe LindseySee RemarksMar 05Sale29.291,73150,70116,176Mar 06 04:45 PM
MUEHL DANIEL WSee RemarksMar 05Sale29.291,29737,9896,177Mar 06 04:45 PM
MUEHL DANIEL WSee RemarksFeb 27Sale25.902666,8895,945Feb 28 06:25 PM